Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones

Bone

Volumn 19, Issue 3, 1996, Pages 281-290

  Masarachia, Patricia J ^a   Weinreb, M ^b   Balena, R ^c   Rodan, G A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Alendronate; Distribution; Etidronate; Mouse bone; Rat bone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; DIAGNOSTIC AGENT; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; MINERALIZATION; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BAGG ALBINO MOUSE; BONE DEVELOPMENT; CHEMISTRY; COMPARATIVE STUDY; MALE; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; ETIDRONIC ACID; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, SPRAGUE-DAWLEY; TRITIUM;

EID: 0030227986     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(96)00182-2     Document Type: Article

References (40)

1. 1. Attie, M. F. Bisphosphonate therapy for osteoporosis. Hosp Pract 26:87-90; 1991.
2. 2. Averbuch, S. D. New bisphosphonates in the treatment of bone metastases. Cancer 72:3443-3452; 1993.
3. 3. Avioli, L. V. Therapy with bisphosphonates, sodium fluoride, thiazides, and vitamin D metabolites. In: Avioli, L. V., Ed. The osteoporotic syndrome: Detection, prevention, and treatment, 3rd ed. New York: Wiley; 1993; 155-169.
4. 4. Axelrod, D. W. and Teitelbaum, S. L. Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates. J Bone Miner Res 9(Suppl 1):S136; 1994.
5. 5. Azuma, Y., Sato, H., Oue, Y., Okabe, K., Tsuchimoto, M., and Kiyoki, M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245; 1995.
6. 6. Boyce, B. F., Smith, L., Fogelman, I., Johnston, E., Ralston, S., and Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1:821-824; 1984.
7. 7. Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P.H., and Blair, H. C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-561; 1990.
8. 8. Dunn, C. J., Fitton, A., and Sorkin, E. M. Etidronic acid, a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 5:446-474; 1994.
9. 9. Evans, R. A., Howlett, C. R., Dunstan, C. R., and Hills, E. The effect of long-term low dose disphosphonate treatment on rat bone. Clin Orthop 165:290-9; 1982.
10. 10. Felix, R., Bettex, J. D., and Fleisch, H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 33:549-52; 1981.
11. 11. Flanagan, A. M. and Chambers, T. J. Inhibition of bone resorption by bisphosphonates: Interaction between bisphosphonates, osteoclasts and bone. Calcif Tissue Int 49:407-15; 1991.
12. 12. Fleisch, H. Bisphosphonates: history and experimental basis. Bone 8:528-38; 1987.
13. 13. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-44; 1991.
14. 14. Fleisch, H. New bisphosphonates in osteoporosis. Osteopor Int 2:S15-22; 1993.
15. 15. Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., and Porras, A. G. Clinical pharmacology of alendronate sodium. Osteopor Int 3(Suppl 3):S13-16; 1993.
16. 16. Gibbs, C. J., Aaron, J. E., and Peacock, M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J 292:1227-1229; 1986.
17. 17. Harris, S. T., Gertz, B. J., Genant, H. K., Eyre, D. R., Survill, T. T., Ventura, J. N., DeBrock, J., Ricerca, E., and Chesnut, C. H. 3rd. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early post-menopausal women. J Clin Endocrin Metab 76:1399-406; 1993.
18. 18. Jee, W. S. S. The Skeletal Tissues. In: Weiss, L., Ed. Histology. New York: Elsevier; 1983; 200-255.
19. 19. Jowsey, J., Riggs, B. L., Kelly, P. J., Hoffman, D. L., and Bordier, P. The treatment of osteoporosis with disodium ethane-1-hydrosy-1,1-diphosphate. J Lab Clin Med 78:574-584; 1971.
20. 20. Jung, A., Bisaz, S., and Fleisch, H. The binding of pyrophosphate and two disphosphonates by hydroxyapatite crystals. Calcif Tiss Res 11:269-280; 1973.
21. 21. Khairi, M. R. A., Altman, R. D., DeRosa, G. P., Zimmermann, J., Schenk, R. D., and Johnston, C. C. Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med 87:656-663; 1977.
22. 22. Lin, J. H., Duggan, D. E., Chen, I. W., and Ellisworth, R. L. Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932; 1991.
23. 23. Lin, J. H., Chen, I. Wu, and Duggan, D. E. Effects of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478; 1992.
24. 24. Mautalen, C., Gonzalez, D., Blumenfeld, E., Arajuo, E. S., and Schajowicz, F. Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate. Clin Orthop Relat Res 207:150-155; 1966.
25. 25. Michael, W. R., King, W. R., and Wakim, J. M. Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxic Appl Pharm 21:503-515; 1972.
26. 26. Miller, S. C., Jee, W. S., Kimmel, D. B., and Woodbury, L. Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calcif Tissue Res 22:243-52; 1977.
27. 27. Miller, S. C. and Jee, W. S. Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on growth and modeling of the rat tibia. Calcif Tissue Res 18:215-231; 1975.
28. 28. Papapoulos, S. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 5A:48-52; 1993.
29. 29. Reitsma, P. H., Teitelbaum, S. L., Bijvoet, O. L. M., and Kahn, A. J. Differential action of bisphosphonates (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (C12MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 70:927-933; 1982.
30. 30. Rodan, G. and Balena, R. Bisphosphonates in the treatment of metabolic bone diseases. Ann Med 25:373-378; 1993.
31. 31. Rodan, G. A., Seedor, J. G., and Balena, R. Preclinical pharmacology of alendronate. Osteopor Int 3:S7-12; 1993.
32. 32. Sahni, M., Guenther, H. L., Martin, T. J., and Fleisch, H. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-11; 1992.
33. 33. Sato, M. and Grasser, W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40; 1990.
34. 34. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-105; 1991.
35. 2MDP on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214; 1973.
36. 36. Schenk, R., Eggli, P., Fleisch, H., and Rosini, S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Res 38:342-349; 1986.
37. 37. Seedor, J. G., Balena, R., Masarachia, P., and Rodan, G. A. Comparison of the therapeutic potencies of two bisphosphonates. Bone 13:A29; 1992.
38. 38. van der Pluijm, G., Binderup, L., Bramm, E., van der WeePals, L., de Groot, H., Binderup, E., Lowik, C., and Papapoulos, S. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J Bone Miner Res 7:981-986; 1992.
39. 39. Wingen, F. and Schmähl, D. Pharmacokinetics of the osteotropic disphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Arzneim Forsch Drug Res 37:1037-1042; 1987.
40. + permeability and intracellular pH regulation in mammalian osteoclastic cells. Bone Miner 25(Suppl 1):S70; 1994.